



July 22, 2021

**VIA EDGAR**

Christine Westbrook  
Division of Corporation Finance  
United States Securities and Exchange Commission  
100 F Street, NE  
Washington, D.C. 20549

Re: Oramed Pharmaceuticals Inc.  
Registration Statement on Form S-3  
File No. 333-257926

Dear Sir or Madam:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oramed Pharmaceuticals Inc. (the "Registrant") hereby requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 4:30 p.m., Eastern Time, on July 26, 2021, or as soon as practicable thereafter.

The Registrant respectfully requests that it be notified of such effectiveness by a telephone call to Howard E. Berkenblit of Sullivan & Worcester LLP at (617) 338-2979 and that such effectiveness also be confirmed in writing.

Very truly yours,

Oramed Pharmaceuticals Inc.

By: /s/ David Silberman  
Name: David Silberman  
Title: Chief Financial Officer

**Oramed Ltd.** | 1185 Avenue of the Americas, New York, NY 10036 | [www.oramed.com](http://www.oramed.com)  
Phone: + 1-844-967-2633 | Fax: +972-2-566 0004 | Email: [info@oramed.com](mailto:info@oramed.com)